Study Type
Original Research
Randomized Controlled Trial
Nonrandomized Clinical Trial
Prospective Cohort study
Retrospective Cohort study
Case-Control study
Case Series
Secondary Research
Systematic Review
Meta-analysis
Interventional information
Secondary Interventions
Repeat Ablation
Anterior Temporal Lobectomy
Hemispherectomy
Staged Procedure
Device information
Methods of Stereotaxy
ROSA Robotic Guidance
BrainLab VarioGuide
Leksell Frame
ClearPoint Navigation
Cosman-Roberts-Wells frame
Cranial Stealth navigation system, Medtronic
Framelink
Compass
Integra Frame
Ablation Device
NeuroBlate® System
Visualase® Thermal Therapy System
OmniGuide laser
Target
Hypothalamic Hamartoma
Mesial Temporal Lobe
Amygdala
Multiple Locations Targeted
Hippocampus
entorhinal cortex
frontal lobe
corpus callosum
deep nuclei
parietal lobe
occipital lobe
cerebellum
thalamus
temporal lobe
insular lobe
Length of Procedure
Side
Previously Treated?
Newly Diagnosed
Previously Treated/Recurrent
Accuracy
Entry Point Error
Target Error
Hair
Anesthesia Time
Repositioning
No. of Ablations
Duration of Monitoring
Uni- or multi-focal
Subpopulations
Type of Epilepsy
Drug-resistant Epilepsy
Mesial Temporal Lobe Epilepsy
Temporal Lobe Epilepsy
Insular Epilepsy
Localized Epilepsy
Type of Seizure
Gelastic Seizures
Complex Partial Seizures
Multiple Types of Seizures
Nongelastic Seizures
Focal Seizures
intractable seizures
simple partial seizures
generalized tonic clonic seizures
Multifocal Epilepsy
Duration of Epilepsy
Comorbidities
Mesial Temporal Sclerosis
Tuberous Sclerosis
Periventricular Heterotopias
Focal Cortical Dysplasias
Cortical Dysplasia
Previous stroke
Premature Birth
Hemimegalencephaly
Disease state(s) other than epilepsy treated
Tumor
Glioma
Brain metastases
Radiation necrosis
Meningioma
Brain Tumor
cavernoma
astrocytoma
Preop Medications
Lamotrigine
Norethindrone
Gabapentin
Carbamazepine
Topiramate
Levetiracetam
No. of Anti-Epileptic Drugs
No. of Anti-Seizure Drugs
Age
Mean Age
Median Age
Age Range
Hospital Stay Length
Sex
Seizure Frequency
Follow-up Timepoints
Follow-Up: Reported as Exact/Mean Amount in Time
Follow-Up: 1 mo
Follow-Up: 6 weeks
Follow-Up: 3 mo
Follow-Up: 6-9 mo
Follow-Up: 1 yr
Follow-Up: 1.5 yr
Follow-Up: 2 yr
Follow-Up: >2 yr
Follow-Up: Only reported as a range
Outcomes
Complications/Adverse Events
Neurological
Oculomotor Nerve Palsy
Transient Nerve Palsy
Superior Quadrantanopsia
Short-term Memory Loss
Hemiparesis
Headache
hemorrhage
cranial nerve deficits
Congenital nerve palsy
hematoma
Facial Droop
cognitive decline
hydrocephalus
Surgical
Infections
Erosions
Malposition
Technical malfunction
Thermal Injury
Hypothyroidism
Weight Gain
Pneumonia
Transient Mutism
Weakness
Perioperative Seizures
No Complications
optic neuritis
Suicidal Ideation
Anxiety
Blurry Vision
sensory loss
diabetes
meningitis
pain
cerebral edema
metastatic regrowth
filum terminale ependymoma
motor deficit
Gait Instability
Hemiplegia
Engel Epilepsy Surgery Outcome Scale
Engel Class I
Engel Class I: Broken Up A, B, C, D
Engel Class I: Not Broken Up into A, B, C, D
Engel Class II
Engel Class III
Engel Class IV
Lesion Size
Medication Change Post-surgery
Different Medication Type (Pre-op and Post-op)
No. of Medications Change (Pre-op and Post-op)
International League Against Epilepsy Class
Seizure Free
Seizure Reduction
Neuropsychological
Verbal Learning Retention
Expressive Language Dysfunction
Visual
Visual Deficit
Visual Change
Mortality
Funding
Public
National Institutes of Health
Private
Study Location
USA
Canada
Multinational
UK
India
China
Czech Republic
Switzerland